Venture Capital Investment Trends in Pharma, Q4 2025
Powered by ![]()
All the vital news, analysis, and commentary curated by our industry experts.
This report analyzes the venture capital (VC) investment activity in Q4 2025 in the Pharma sector.
Scope
This report provides an overview of VC investment activity globally in Q4 2025 in the Pharma sector involving biopharmaceutical drug companies.
It identifies key trends, and the most notable deals announced in Q4 2025 in the Pharma sector.
Key Highlights
In Q4 2025, the global pharma sector saw investments totaling $9.6 billion, marking an 70.6% increase from Q3 2025. Investment volume also rose, with 206 deals, representing a 30.4% uptick. Oncology emerged as the top therapy area with 89 deals backed by 325 investors.
Reasons to Buy
Companies that strategically invest in venture funding position themselves for success, while those that fail to adapt risk falling behind.
This report provides an overview of global VC investment trends in the pharma sector from the past quarter, offering insights into the industry landscape and key market movements.
Tubulis
Kardigan
Souffle Therapeutics
Braveheart Bio
Electra Therapeutics
Expedition Therapeutics
Hemab
Veradermics
Adcytherix
TRIANA Biomedicines
Ambros Therapeutics
Aspen Neuroscience
Atavistik Bio
Iambic Therapeutics
Syremis Therapeutics
Table of Contents
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Pharmaceuticals reports